+

WO2003047426A1 - Dispositif d'administration de medicament a fonction de communication avec un indicateur de glycemie - Google Patents

Dispositif d'administration de medicament a fonction de communication avec un indicateur de glycemie Download PDF

Info

Publication number
WO2003047426A1
WO2003047426A1 PCT/US2002/036124 US0236124W WO03047426A1 WO 2003047426 A1 WO2003047426 A1 WO 2003047426A1 US 0236124 W US0236124 W US 0236124W WO 03047426 A1 WO03047426 A1 WO 03047426A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood glucose
injection pen
pen
dose
person
Prior art date
Application number
PCT/US2002/036124
Other languages
English (en)
Inventor
Robert Richardson Nesbitt
Bradley Ray Newman
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to AU2002360370A priority Critical patent/AU2002360370A1/en
Publication of WO2003047426A1 publication Critical patent/WO2003047426A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
    • A61M2005/14506—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons mechanically driven, e.g. spring or clockwork
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3507—Communication with implanted devices, e.g. external control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic

Definitions

  • the present invention pertains to medication delivery devices, and, in particular, to an injection pen that a user operates to selectively inject medication to treat a medical condition.
  • An assortment of differently configured portable injectors broadly known as injection pens have been developed to make it convenient for users to so administer medicine.
  • An injection pen loaded with a multi-dose cartridge of insulin frequently is just one device in a set of devices used by some people with diabetes to control their blood glucose levels.
  • a blood glucose monitoring device may be part of this set and used to test blood glucose values in order for a determination to be made as to, for example, the proper amount of insulin to be injected with the injection pen, or the amount of orally administrable drugs to take, to treat the user's condition.
  • Available cBGMs have included a catheter sensor implanted under the user's skin or in an artery and connected to a base unit outside the body, and are being developed to instead include an equivalent sensor/base unit which is entirely implantable, that wirelessly communicates sensed blood glucose values to a pager-like device which can be attached to the belt of a user.
  • This pager-like device displays the sensor values in a manner similar to more conventional blood glucose monitoring devices, and allows the user to determine what dosage of blood glucose lowering agent, such as insulin, should be administered based on this blood glucose value. For example, based upon this displayed output, the insulin injection pen can be retrieved and manipulated to deliver the dose of insulin calculated to be necessary by the user.
  • cBGMs advantageously eliminate the need to draw blood, substituting such devices for more standard blood glucose monitoring devices does not adequately address handling type issues, as a user still may need to access both an injection pen and a separate pager-like device of the cBGM.
  • the present invention encompasses an injection pen including a wireless communications capability that allow instantaneous blood glucose data received from a transmitting blood glucose monitor to be displayed on an electronic screen of the injection pen. A user can then use this displayed data to determine a proper therapeutic dose of medicine, which dose can be administered by operation of the injection pen.
  • the present invention provides a method of treating diabetes in a person, including the steps of: providing a blood glucose monitor either entirely or at least partially implanted within the person, whereby a blood glucose level of the person is determinable by the blood glucose monitor without manually drawing a blood sample, providing an injection pen including a multi-dose quantity of diabetes medication, receiving with the injection pen via a wireless communication from the blood glucose monitor the determined blood glucose level, displaying the blood glucose level on a display of the injection pen, setting the injection pen to deliver a dose of the diabetes medication based on the displayed blood glucose level, and operating the injection pen to administer to the person the set dose of diabetes medication.
  • One advantage of the present invention is that an injection pen is provided that can be used as part of a convenient diabetes management system that allows for the control of blood glucose levels without frequent finger- sticks or other blood draws.
  • an inventive injection pen is that it is capable of directly communicating with an implanted blood glucose monitor, thereby reducing the amount of equipment that has to be carried around by a user in order to control blood glucose levels by injection.
  • Still another advantage of an inventive injection pen is that it can be programmed to communicate sensed blood glucose levels and treatment history to an external database for review.
  • an inventive injection pen can be part of a diabetes management system that promotes better blood glucose control by making it convenient and painless to frequently determine blood glucose levels, and then conveniently administer medicine in view thereof, as many times per time as may be needed or recommended.
  • Fig. 1 is a front view of an exemplary embodiment of an injection pen of the present invention
  • Fig. 2 is a schematic block diagram of components of the injection pen of Fig. 1;
  • Fig. 3 is a diagrammatic perspective view of the injection pen of Fig. 1 being used to obtain in a wireless fashion a blood glucose reading from a transmitting blood glucose monitor;
  • Fig. 4 is a schematic block diagram of an injection pen of the present invention as part of a diabetes management system.
  • FIG. 20 there is shown an exemplary embodiment of a portable injector or injection pen of the present invention.
  • the shown injection pen, generally designated 20, closely resembles a pen-type writing instrument in appearance, but the injection pen of the present invention may be configured to have a different appearance, including but not limited to the more compact, boxlike appearance of the injection pen known as Innovo® available from Novo Nordisk.
  • Pen 20 is of a reusable or refillable variety, as opposed to a disposable variety in which the entire device would be discarded after its supply of medication is exhausted.
  • ' injection pen 20 includes a medication filled cartridge as part of a cartridge assembly, generally designated 24, which is connected to a reusable pen base, generally designated 26.
  • the shown cartridge assembly is in the form of a reusable retainer 28 with a disposable cartridge 30 filled with multiple doses of medicine loaded therein.
  • Retainer 28 is connectable to the pen base housing, such as via threads.
  • Cartridge 30 is insertable into, and removable when empty for replacement from, the retainer through the open proximal end of the retainer when the retainer is not connected to pen base 26.
  • An injection needle assembly 32 is mountable on the distal end of cartridge assembly 24 such that the proximal end of its needle pierces a not shown septum of the cartridge.
  • the needle assembly may be of various types known in the art, including, but not limited to, assemblies with one or more shortened injection needles, including microneedle arrays. Medicine, such as insulin, is outlet from the internal volume of cartridge 30 through the needle when a piston 31 within the cartridge is moved toward the needle assembly in a conventional manner during injecting use of pen 20.
  • the cartridge assembly may be differently configured, such as is known in the art.
  • the cartridge assembly may include a distal cap that holds an inserted cartridge within a retainer portion extending from the pen housing, or may be assembled from component parts during its production into a unit handleable by a user as a single piece, and disposed of as a unit when the contained medicine is exhausted.
  • Pen base 26 includes components that function to allow any one of a number of quantities of medicine to be selected and then expelled from cartridge 30 at a given time through the attached injection needle assembly 32.
  • those components include a manually operable dosage knob 34 and a mechanical drive mechanism 36 which is protectively housed within the pen base and operably connected to knob 34.
  • Dosage knob 34 is rotatable in either direction to set the dose to be injected, or in other words control the distance the drive member will advance when the dosage knob 34 is plunged.
  • Drive mechanism 36 includes a drive member that advances to shift piston 31 distally and force medication from cartridge 30 when dosage knob 34 is plunged after having been rotated to set a dose.
  • dosage knob 34 may move out relative to the pen base when rotated to increase the set dose, and then move in relative to the pen base when rotated to decrease the set dose, such axial motion during dose setting is a function of the drive mechanism to which it operatively attaches, and the dosage knob 34 need not so move to fall within the scope of the invention.
  • the element actuated to cause the drive mechanism to advance the cartridge piston 31 is described herein as the knob 34 used to set the dose, but may be a different actuating element within the scope of the invention.
  • a battery-powered electronics package of pen 20 includes a microprocessor 40 within pen base 26.
  • Microprocessor 40 is circuited with one or more memory storage elements 42 and a display or screen 44 on which displayed data is visible to a user.
  • One or more control buttons 46 may be' used to control the operation of pen 20, such as to manually input data to the microprocessor, such as corrections to the time and date determined by a clock contained within the electronics package of pen 20.
  • a sensor 48 senses knob 34 to input to microprocessor 40 the dosage selected by knob rotation, which sensed dosage can be displayed on screen 44.
  • Microprocessor 40 causes the sensed dosage, as well as one or more previous dosages if desired, to be saved in memory storage elements 42 along with the time and day of their administrations for later recall.
  • pen 20 as an electronic injection pen that automatically senses and displays a dose selected for injection, and which effects a dose delivery by a strictly mechanical interconnection between a plungable dose knob and the cartridge piston advancing drive member.
  • Such general description is merely provided as background and is intended to be illustrative and not limiting in any way.
  • a variety of injection pens are known in the art which include different mechanisms for setting and administering doses, and these pens may be readily adapted to include the specific communications module and practice the invention as further described herein. Possible such pens are not limited to and include, for example, those disclosed in U.S. Patents No. 5,925,021 and 5,928,201 and European Patent Application EP 1095668 Al .
  • Injection pen 20 further includes a communications module 52 within pen base 26 and electrically circuited to microprocessor 40.
  • Communications module 52 includes hardware that serves as an input port, and optionally an output port as described further below, for communicating as instructed by microprocessor 40 with a device distinct from and external to the injection pen 20.
  • Communications module 52 is preferably configured for wireless communications, with the external device, although infrared and direct plug-in physical connections may be employed in embodiments in which the external device is physically accessible .
  • Injection pen 20 receives input from a blood glucose monitor (BGM) 60 that is implanted in a person 62 who can use pen 20 to inject medication.
  • BGM 60 is shown diagrammatically in Fig. 4, and includes a system for determining a blood glucose level and a transmitter for transmitting that blood glucose level to communications module 52 of pen 20.
  • BGM 60 can be of the type entirely implanted under the skin of the user.
  • BGM 60 can be of the type only partially implanted under the skin of the user, such as a sensor element within a cannula that implants under the skin to access blood within the user, and with other aspects of the BGM, such as the transmitter, being housed within a unit mounted to the user's skin.
  • BGM 60 determines blood glucose levels without the user 62 having blood manually removed from her body, thereby eliminating the need for a blood-drawing via a conventional lancet finger-stick.
  • BGM 60 can be an active unit, such as a continuous blood glucose monitor which continuously senses and transmits blood glucose levels to any pen with a communications module brought into the range of its transmitted signal.
  • BGM 60 alternatively can be a passive unit that is only briefly activated when signaled by injection pen 20. For example, a signal from communications module 52 can turn on a power source within, or directly energize, the BGM that then sends a blood glucose indicating signal back to pen 20. For that passive BGM unit, communications module 52 provides both a transmitting function and a receiving function.
  • BGMs of these general types are known in the art, such as disclosed in U.S. Patent No. 6,201,980 Bl, and International Patent Applications WO 99/48419 and WO 00/49940, and are therefore only briefly described herein.
  • the structure of a diabetes management system using pen 20 will be further understood in view of the following explanation of its operation.
  • person 62 believes it appropriate to check her blood glucose level, she retrieves pen 20 and brings it into proximity with BGM 60. If BGM 60 is in a passive mode, injection pen 20 can be properly manipulated to send a signal that, for example, awakens BGM 60.
  • BGM 60 determines and wirelessly transmits a signal as to the person's blood glucose level to pen 20, which signal is received by module 52 and processed by microprocessor 40 such that the blood glucose level is caused to be visually displayed on electronic screen 44.
  • Person 62 is then able to read the displayed blood glucose level from screen 44 and, preferably after priming the pen with an air shot in a known manner, to manually rotate dosage knob 34 to set injection pen 20 to deliver a proper amount of medication, such as insulin, from pen cartridge 30 to treat the condition reflected by that blood glucose reading.
  • injection pen 20 is manipulated such that needle 32 penetrates the skin of the user at the appropriate injection site, and dosage knob 34 is plunged to cause drive mechanism 36 to administer the set dose of medication through the needle to the patient.
  • the administered dose possibly along with prior administered doses as well as, for example, the times and dates at which such doses were administered, can be automatically stored in memory 42 for later reference.
  • an embodiment of an injection pen 20 of the present invention is shown as part of a diabetes management system in which it is utilized both to collect data from a downstream, implanted blood glucose monitor 60, and then to transmit that collected data, along with data it may generate, to a second external device 70 which is upstream in a data chain.
  • the shown injection pen can serve as an integral and intermediate part of a chain by which diabetes treatment history data can be communicated to, for example, a treating medical professional, for further consideration.
  • injection pen 20 is capable of storing blood glucose levels received from BGM 60, as well as dosing information it develops during use. That information is all communicated at 68 to an external device indicated at 70. For example, via communications module 52, pen 20 can transmit that information, preferably in a wireless fashion but alternatively via a plug-in style connection, to a device 70 that is a personal digital assistant (PDA) loaded with patient data software.
  • PDA personal digital assistant
  • the software allows the person to also directly enter into the PDA data such as food intake and physical activity.
  • a treating physician can view the data on the PDA to assess the medical history of the person, or download the data from the PDA, such as via either a wireless or plug-in style connection, to, for example, a database on a stand-alone or networked computer for later consideration.
  • Device 70 shown in Fig. 4 alternatively may be such stand-alone or networked computer.
  • device 70 to which pen 20 is shown communicating in Fig. 4 alternatively may be a cell phone, or pager-style device similarly capable of transmitting information, which relays the data to, for example, a website or networked computer system, which cell phone or pager-style device also may possibly be used to relay other data such as food intake or physical activity.
  • the cell phone or pager-style device alternatively may be used as an amplifier to get the data to a satellite for transmission, and further the cell phone or pager-style device could have a capability for, at the touch of a single emergency button provided thereon, calling in an emergency, such as to locations further described below, if the patient recognized that the blood glucose value provided to pen 20 by BGM 60 indicates, for example, that the patient is having a hypoglycemic attack, and then the patient pressed such button.
  • the cell phone or pager-style device if provided with global positioning system capabilities, could also be used by a patient to signal where exactly he or she is located if the emergency button on the phone or device were pressed.
  • the diabetes management system utilizing injection pen 20 can be adapted to signal for emergency assistance without action by the patient.
  • injection pen 20 could be configured so as to automatically trigger a cell phone or pager-style device 70 to call (i.e., without patient intervention) for such exigent circumstances as could be envisioned when the patient's blood glucose values get to such a low level that a patient could be at risk that imminent harm may ensue.
  • One such system involves a continuously broadcasting blood glucose monitor 60, and an injection pen 20 constantly in a receiving mode and in communication with the monitor 60 when in sufficient proximity to the patient, preferably while in the patient's pocket.
  • pen 20 When the blood glucose signal received from monitor 60 by pen 20 is recognized by pen 20 as being below a preset danger level, which preset danger level is patient- appropriate and set up or preprogrammed in the pen 20 by the patient's physician and/or the equipment supplier, pen 20, besides possibly creating an audible alarm to notify the patient, automatically causes the cell phone or pager-style device 70 to signal for help without intervention by the patient.
  • the phone or pager-style device signals for help by contacting, for example, a doctor's office or pager, or an emergency service provider.
  • the injection pen 20 could be configured to awaken periodically without intervention by the patient, and when awakened to energize the "sleeping" BGM in proximity thereto to cause a blood glucose value to be determined and broadcast to the pen, which pen, if necessary, then works to have an emergency signaled in the above-described manner.
  • the wireless communications protocol by which pen 20 communicates may be one known in the art, such as the "Bluetooth" protocol.
  • Other suitable protocols by which pen 20 can communicate may be used, and include, but are not limited to, the IEEE 802.11 protocol.
  • the injection pen of the present invention may be a needle-free or jet injector device, and further may employ electromechanical components or biasing members such as springs to assist the dosing or injecting process.
  • the dose could be automatically set in the pen with an electric motor based on the communicated blood glucose level.
  • the external device 70 could be provided with dosing information directly by the injection pen, and blood glucose level information directly by the blood glucose monitor.
  • user operable medication delivery devices other than an injection pen such as pulmonary devices like a dry power inhaler, may be adapted to practice the present invention.
  • This application is therefore intended to cover any variations, uses or adaptations of the invention using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this invention pertains .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un procédé de traitement d'état pathologique (par exemple, diabète) chez un patient, qui comprend les étapes suivantes: fourniture d'un indicateur de glycémie implanté entièrement ou au moins en partie dans le corps du patient, pour déterminer un taux de glycémie sans prélèvement manuel d'échantillon de sang; fourniture d'un stylo injecteur contenant une certaine quantité de médicament à doses multiples contre le diabète; réception sur le stylo injecteur, en mode de communication sans fil, du taux de glycémie déterminé, depuis l'indicateur de glycémie; affichage de ce taux sur un visuel du stylo injecteur; réglage du stylo injecteur pour l'administration d'une dose de médicament contre le diabète, en fonction du taux de glycémie affiché; et utilisation du stylo injecteur pour l'administration au patient de la dose établie de médicament contre le diabète.
PCT/US2002/036124 2001-12-03 2002-11-25 Dispositif d'administration de medicament a fonction de communication avec un indicateur de glycemie WO2003047426A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002360370A AU2002360370A1 (en) 2001-12-03 2002-11-25 Medication delivery device having communication capability with glucose monitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33776601P 2001-12-03 2001-12-03
US60/337,766 2001-12-03

Publications (1)

Publication Number Publication Date
WO2003047426A1 true WO2003047426A1 (fr) 2003-06-12

Family

ID=23321906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036124 WO2003047426A1 (fr) 2001-12-03 2002-11-25 Dispositif d'administration de medicament a fonction de communication avec un indicateur de glycemie

Country Status (2)

Country Link
AU (1) AU2002360370A1 (fr)
WO (1) WO2003047426A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032652A1 (fr) * 2004-09-23 2006-03-30 Novo Nordisk A/S Telecommande destinee a etre utilisee avec un dispositif de dispensation de medicament
WO2006045525A1 (fr) * 2004-10-21 2006-05-04 Novo Nordisk A/S Dispositif d'injection comprenant un processeur conçu pour recueillir des informations d'ejection
US7713229B2 (en) 2003-11-06 2010-05-11 Lifescan, Inc. Drug delivery pen with event notification means
EP2284275A1 (fr) 2009-08-10 2011-02-16 Sensile Pat AG Membrane à réponse de stimuli
CN102548467A (zh) * 2008-07-18 2012-07-04 生命扫描有限公司 分析物测量和管理装置及相关方法
US8221356B2 (en) 2004-10-21 2012-07-17 Novo Nordisk A/S Medication delivery system with a detector for providing a signal indicative of an amount of a set and/or ejected dose of drug
US8292826B1 (en) 2011-06-21 2012-10-23 YofiMETER, Inc. Cocking and advancing mechanism for analyte testing device
EP2572740A1 (fr) * 2011-09-20 2013-03-27 Roche Diagnostics GmbH Dispositifs d'injection de médicaments et systèmes avec un module de mesure de substance à analyser
US8556865B2 (en) 2009-02-27 2013-10-15 Lifescan, Inc. Medical module for drug delivery pen
US20130274577A1 (en) * 2012-04-16 2013-10-17 PicoLife Technologies Medication Delivery Device and Related Methods of Use
US8663538B2 (en) 2009-02-12 2014-03-04 Picolife Technologies, Llc Method of making a membrane for use with a flow control system for a micropump
EP2705850A2 (fr) 2008-04-28 2014-03-12 Halozyme, Inc. Super fast-acting insulin compositions
US8771229B2 (en) 2011-12-01 2014-07-08 Picolife Technologies, Llc Cartridge system for delivery of medicament
US8790307B2 (en) 2011-12-01 2014-07-29 Picolife Technologies, Llc Drug delivery device and methods therefor
US8961432B2 (en) 2011-06-21 2015-02-24 Yofimeter, Llc Analyte testing devices
US9101723B2 (en) 2006-03-20 2015-08-11 Novo Nordisk A/S Electronic module for mechanical medication delivery devices
WO2016038498A1 (fr) * 2014-09-08 2016-03-17 Medaxor Pty Ltd Système d'injection
US9501949B2 (en) 2004-10-07 2016-11-22 Novo Nordisk A/S Method and system for self-management of a disease
US9619625B2 (en) 2011-03-30 2017-04-11 Novo Nordisk A/S System for optimizing a patient's drug dosage regimen over time
US9883834B2 (en) 2012-04-16 2018-02-06 Farid Amirouche Medication delivery device with multi-reservoir cartridge system and related methods of use
EP2729202B1 (fr) 2011-07-07 2018-05-16 Novo Nordisk A/S Injecteur de type stylo avec module de mesure et d'affichage de dose
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US10130759B2 (en) 2012-03-09 2018-11-20 Picolife Technologies, Llc Multi-ported drug delivery device having multi-reservoir cartridge system
US10245420B2 (en) 2012-06-26 2019-04-02 PicoLife Technologies Medicament distribution systems and related methods of use
US10682469B2 (en) 2017-12-04 2020-06-16 Novo Nordisk A/S Drug delivery system with magnetic ring and sensors arranged in a ring pattern
US10704944B2 (en) 2014-09-14 2020-07-07 Becton, Dickinson And Company System and method for capturing dose information
US10971260B2 (en) 2014-09-14 2021-04-06 Becton, Dickinson And Company System and method for capturing dose information
US10987472B2 (en) 2017-02-28 2021-04-27 Eli Lilly And Company Dose detection for a medication delivery device
US20210186328A1 (en) * 2004-02-26 2021-06-24 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US11596747B2 (en) 2017-09-22 2023-03-07 Novo Nordisk A/S Accessory device for drug delivery device
US11660401B2 (en) 2017-12-21 2023-05-30 Sanofi Drug delivery device with non-contact sensor
US11857770B2 (en) 2018-02-22 2024-01-02 Eli Lilly And Company Medication delivery device with a sensed element
US12115357B2 (en) 2004-02-26 2024-10-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US12239826B2 (en) 2018-12-04 2025-03-04 Novo Nordisk A/S Drug delivery assembly with moving sensor system
US12246166B2 (en) 2007-10-09 2025-03-11 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569186A (en) * 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5925021A (en) * 1994-03-09 1999-07-20 Visionary Medical Products, Inc. Medication delivery device with a microprocessor and characteristic monitor
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
WO2000049940A2 (fr) * 1999-02-25 2000-08-31 Minimed Inc. Systeme boitier pour capteur de glucose
EP1095668A1 (fr) * 1999-11-01 2001-05-02 Becton Dickinson and Company Crayon électronique à injection avec sélecteur de multifonction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925021A (en) * 1994-03-09 1999-07-20 Visionary Medical Products, Inc. Medication delivery device with a microprocessor and characteristic monitor
US5569186A (en) * 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
WO2000049940A2 (fr) * 1999-02-25 2000-08-31 Minimed Inc. Systeme boitier pour capteur de glucose
EP1095668A1 (fr) * 1999-11-01 2001-05-02 Becton Dickinson and Company Crayon électronique à injection avec sélecteur de multifonction

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713229B2 (en) 2003-11-06 2010-05-11 Lifescan, Inc. Drug delivery pen with event notification means
US8551039B2 (en) 2003-11-06 2013-10-08 Lifescan, Inc. Drug delivery with event notification
US12115357B2 (en) 2004-02-26 2024-10-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20210186328A1 (en) * 2004-02-26 2021-06-24 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US12226617B2 (en) 2004-02-26 2025-02-18 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US12102410B2 (en) 2004-02-26 2024-10-01 Dexcom, Inc Integrated medicament delivery device for use with continuous analyte sensor
WO2006032652A1 (fr) * 2004-09-23 2006-03-30 Novo Nordisk A/S Telecommande destinee a etre utilisee avec un dispositif de dispensation de medicament
US9501949B2 (en) 2004-10-07 2016-11-22 Novo Nordisk A/S Method and system for self-management of a disease
US8221356B2 (en) 2004-10-21 2012-07-17 Novo Nordisk A/S Medication delivery system with a detector for providing a signal indicative of an amount of a set and/or ejected dose of drug
US11318251B2 (en) 2004-10-21 2022-05-03 Novo Nordisk A/S Injection device with a processor for collecting ejection information
US10383996B2 (en) 2004-10-21 2019-08-20 Novo Nordisk A/S Injection device with a processor for collecting ejection information
WO2006045525A1 (fr) * 2004-10-21 2006-05-04 Novo Nordisk A/S Dispositif d'injection comprenant un processeur conçu pour recueillir des informations d'ejection
US9101723B2 (en) 2006-03-20 2015-08-11 Novo Nordisk A/S Electronic module for mechanical medication delivery devices
US12246166B2 (en) 2007-10-09 2025-03-11 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
EP2705850A2 (fr) 2008-04-28 2014-03-12 Halozyme, Inc. Super fast-acting insulin compositions
US9034323B2 (en) 2008-04-28 2015-05-19 Halozyme, Inc. Method for control of post-prandial glucose
WO2010009382A3 (fr) * 2008-07-18 2012-08-02 Lifescan, Inc. Dispositif de gestion et de mesure d'analyte, et procédés associés
CN102548467A (zh) * 2008-07-18 2012-07-04 生命扫描有限公司 分析物测量和管理装置及相关方法
US8807169B2 (en) 2009-02-12 2014-08-19 Picolife Technologies, Llc Flow control system for a micropump
US8663538B2 (en) 2009-02-12 2014-03-04 Picolife Technologies, Llc Method of making a membrane for use with a flow control system for a micropump
US9724475B2 (en) 2009-02-27 2017-08-08 Lifescan, Inc. Drug delivery management systems and methods
US8556867B2 (en) 2009-02-27 2013-10-15 Lifescan, Inc. Drug delivery management systems and methods
US8556865B2 (en) 2009-02-27 2013-10-15 Lifescan, Inc. Medical module for drug delivery pen
US8556866B2 (en) 2009-02-27 2013-10-15 Lifescan, Inc. Drug delivery system
WO2011018752A1 (fr) 2009-08-10 2011-02-17 Sensile Pat Ag Membrane sensible aux stimulis
EP2284275A1 (fr) 2009-08-10 2011-02-16 Sensile Pat AG Membrane à réponse de stimuli
US9619625B2 (en) 2011-03-30 2017-04-11 Novo Nordisk A/S System for optimizing a patient's drug dosage regimen over time
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US8292826B1 (en) 2011-06-21 2012-10-23 YofiMETER, Inc. Cocking and advancing mechanism for analyte testing device
US8961432B2 (en) 2011-06-21 2015-02-24 Yofimeter, Llc Analyte testing devices
EP2729202B1 (fr) 2011-07-07 2018-05-16 Novo Nordisk A/S Injecteur de type stylo avec module de mesure et d'affichage de dose
EP2572740A1 (fr) * 2011-09-20 2013-03-27 Roche Diagnostics GmbH Dispositifs d'injection de médicaments et systèmes avec un module de mesure de substance à analyser
US10213549B2 (en) 2011-12-01 2019-02-26 Picolife Technologies, Llc Drug delivery device and methods therefor
US9993592B2 (en) 2011-12-01 2018-06-12 Picolife Technologies, Llc Cartridge system for delivery of medicament
US8771229B2 (en) 2011-12-01 2014-07-08 Picolife Technologies, Llc Cartridge system for delivery of medicament
US8790307B2 (en) 2011-12-01 2014-07-29 Picolife Technologies, Llc Drug delivery device and methods therefor
US10130759B2 (en) 2012-03-09 2018-11-20 Picolife Technologies, Llc Multi-ported drug delivery device having multi-reservoir cartridge system
US20130274577A1 (en) * 2012-04-16 2013-10-17 PicoLife Technologies Medication Delivery Device and Related Methods of Use
WO2013158430A1 (fr) * 2012-04-16 2013-10-24 PicoLife Technologies Dispositif d'administration de médicament et procédés d'utilisation associés
US9883834B2 (en) 2012-04-16 2018-02-06 Farid Amirouche Medication delivery device with multi-reservoir cartridge system and related methods of use
US10245420B2 (en) 2012-06-26 2019-04-02 PicoLife Technologies Medicament distribution systems and related methods of use
WO2016038498A1 (fr) * 2014-09-08 2016-03-17 Medaxor Pty Ltd Système d'injection
US10704944B2 (en) 2014-09-14 2020-07-07 Becton, Dickinson And Company System and method for capturing dose information
US10971260B2 (en) 2014-09-14 2021-04-06 Becton, Dickinson And Company System and method for capturing dose information
US11541186B2 (en) 2017-02-28 2023-01-03 Eli Lilly And Company Dose detection and drug identification for a medication delivery device
US11426527B2 (en) 2017-02-28 2022-08-30 Eli Lilly And Company Dose detection for a medication delivery device
US10987472B2 (en) 2017-02-28 2021-04-27 Eli Lilly And Company Dose detection for a medication delivery device
US12151088B2 (en) 2017-02-28 2024-11-26 Eli Lilly And Company Dose detection for a medication delivery device
US11596747B2 (en) 2017-09-22 2023-03-07 Novo Nordisk A/S Accessory device for drug delivery device
US11684722B2 (en) 2017-12-04 2023-06-27 Novo Nordisk A/S Drug delivery system with multipolar magnet and sensor system
US10682469B2 (en) 2017-12-04 2020-06-16 Novo Nordisk A/S Drug delivery system with magnetic ring and sensors arranged in a ring pattern
US11660401B2 (en) 2017-12-21 2023-05-30 Sanofi Drug delivery device with non-contact sensor
US11857770B2 (en) 2018-02-22 2024-01-02 Eli Lilly And Company Medication delivery device with a sensed element
US12233246B2 (en) 2018-02-22 2025-02-25 Eli Lilly And Company Dose detection system module for a medication delivery device
US12239826B2 (en) 2018-12-04 2025-03-04 Novo Nordisk A/S Drug delivery assembly with moving sensor system

Also Published As

Publication number Publication date
AU2002360370A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003047426A1 (fr) Dispositif d'administration de medicament a fonction de communication avec un indicateur de glycemie
CN100400118C (zh) 具有遥控设备的医学装置
US5925021A (en) Medication delivery device with a microprocessor and characteristic monitor
EP2502172B1 (fr) Systèmes pour traitement de l'hypoglycémie
US7544185B2 (en) Needle device comprising a plurality of needles
EP3174576B1 (fr) Dispositif d'injection pour surveillance continue du glucose
EP1406540B1 (fr) Procede et systeme de controle d'informations de donnees entre deux appareils medicaux portatifs
EP1525014B1 (fr) Systeme d'envoi de mesures de la glycemie a un dispositif de perfusion
US8206340B2 (en) Integrated glucose monitor and insulin injection pen with automatic emergency notification
US20120227737A1 (en) Analyte sensor and method of using the same
JP2003290345A (ja) 輸液投与および特定成分モニタを遠隔制御するシステムおよび方法
JPH11507250A (ja) 血液グルコースデータの入力を備えた薬剤注入装置
EP1079876A1 (fr) Appareil a usage medical permettant a un diabetique de s'administrer tout seul son traitement
JP2004524869A (ja) 患者の輸液システム用のデータ収集アセンブリ
JP2009504322A (ja) 輸液ポンプのためのハンドヘルド制御装置デバイス
EP2315549A2 (fr) Dispositif de gestion et de mesure d'analyte, et procédés associés
JP2009504323A (ja) 輸液ポンプのための制御装置デバイス
US20210252229A1 (en) Universal smart cap for pen injectors
JP2023547775A (ja) プライミングペン事象と治療ペン事象とを判別するための薬剤注射ペン
DK200200304U3 (da) Nåleenhed og medicinsk afleveringsapparat
CA2222070C (fr) Dispositif de perfusion medicale permettant l'introduction de donnees sur la teneur en glucose sanguin
CN119585808A (zh) 智能注射系统

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载